625 related articles for article (PubMed ID: 19836346)
1. Effects of exendin-4 on glucose tolerance, insulin secretion, and beta-cell proliferation depend on treatment dose, treatment duration and meal contents.
Arakawa M; Ebato C; Mita T; Hirose T; Kawamori R; Fujitani Y; Watada H
Biochem Biophys Res Commun; 2009 Dec; 390(3):809-14. PubMed ID: 19836346
[TBL] [Abstract][Full Text] [Related]
2. Durable islet effects on insulin secretion and protein kinase A expression following exendin-4 treatment of high-fat diet-fed mice.
Winzell MS; Ahrén B
J Mol Endocrinol; 2008 Feb; 40(2):93-100. PubMed ID: 18234911
[TBL] [Abstract][Full Text] [Related]
3. Glucagon-like peptide-1 and islet lipolysis.
Sörhede Winzell M; Ahrén B
Horm Metab Res; 2004; 36(11-12):795-803. PubMed ID: 15655711
[TBL] [Abstract][Full Text] [Related]
4. The glucagon-like peptide-1 receptor agonist oxyntomodulin enhances beta-cell function but does not inhibit gastric emptying in mice.
Maida A; Lovshin JA; Baggio LL; Drucker DJ
Endocrinology; 2008 Nov; 149(11):5670-8. PubMed ID: 18669601
[TBL] [Abstract][Full Text] [Related]
5. Exendin-4 upregulates the expression of Wnt-4, a novel regulator of pancreatic β-cell proliferation.
Heller C; Kühn MC; Mülders-Opgenoorth B; Schott M; Willenberg HS; Scherbaum WA; Schinner S
Am J Physiol Endocrinol Metab; 2011 Nov; 301(5):E864-72. PubMed ID: 21771967
[TBL] [Abstract][Full Text] [Related]
6. An albumin-exendin-4 conjugate engages central and peripheral circuits regulating murine energy and glucose homeostasis.
Baggio LL; Huang Q; Cao X; Drucker DJ
Gastroenterology; 2008 Apr; 134(4):1137-47. PubMed ID: 18313669
[TBL] [Abstract][Full Text] [Related]
7. Potentiation of insulin secretion and improvement of glucose intolerance by combining a novel G protein-coupled receptor 40 agonist DS-1558 with glucagon-like peptide-1 receptor agonists.
Nakashima R; Yano T; Ogawa J; Tanaka N; Toda N; Yoshida M; Takano R; Inoue M; Honda T; Kume S; Matsumoto K
Eur J Pharmacol; 2014 Aug; 737():194-201. PubMed ID: 24858371
[TBL] [Abstract][Full Text] [Related]
8. Exendin-4, a glucagon-like peptide-1 receptor agonist, inhibits cell apoptosis induced by lipotoxicity in pancreatic β-cell line.
Wei Q; Sun YQ; Zhang J
Peptides; 2012 Sep; 37(1):18-24. PubMed ID: 22776329
[TBL] [Abstract][Full Text] [Related]
9. The effects of exendin-4 treatment on graft failure: an animal study using a novel re-vascularized minimal human islet transplant model.
Sahraoui A; Winzell MS; Gorman T; Smith DM; Skrtic S; Hoeyem M; Abadpour S; Johansson L; Korsgren O; Foss A; Scholz H
PLoS One; 2015; 10(3):e0121204. PubMed ID: 25793295
[TBL] [Abstract][Full Text] [Related]
10. Long-term metabolic benefits of exenatide in mice are mediated solely via the known glucagon-like peptide 1 receptor.
Tatarkiewicz K; Sablan EJ; Polizzi CJ; Villescaz C; Parkes DG
Am J Physiol Regul Integr Comp Physiol; 2014 Apr; 306(7):R490-8. PubMed ID: 24477544
[TBL] [Abstract][Full Text] [Related]
11. Comparison of independent and combined metabolic effects of chronic treatment with (pGlu-Gln)-CCK-8 and long-acting GLP-1 and GIP mimetics in high fat-fed mice.
Irwin N; Hunter K; Montgomery IA; Flatt PR
Diabetes Obes Metab; 2013 Jul; 15(7):650-9. PubMed ID: 23388064
[TBL] [Abstract][Full Text] [Related]
12. Acute but not chronic activation of brain glucagon-like peptide-1 receptors enhances glucose-stimulated insulin secretion in mice.
Tudurí E; Beiroa D; Porteiro B; López M; Diéguez C; Nogueiras R
Diabetes Obes Metab; 2015 Aug; 17(8):789-99. PubMed ID: 25962313
[TBL] [Abstract][Full Text] [Related]
13. Poly-GLP-1, a novel long-lasting glucagon-like peptide-1 polymer, ameliorates hyperglycaemia by improving insulin sensitivity and increasing pancreatic beta-cell proliferation.
Ma X; Hui H; Liu Z; He G; Hu J; Meng J; Guan L; Luo X
Diabetes Obes Metab; 2009 Oct; 11(10):953-65. PubMed ID: 19531053
[TBL] [Abstract][Full Text] [Related]
14. A novel GLP-1/xenin hybrid peptide improves glucose homeostasis, circulating lipids and restores GIP sensitivity in high fat fed mice.
Hasib A; Ng MT; Khan D; Gault VA; Flatt PR; Irwin N
Peptides; 2018 Feb; 100():202-211. PubMed ID: 29412820
[TBL] [Abstract][Full Text] [Related]
15. Exendin-4 potentiates insulinotropic action partly via increasing beta-cell proliferation and neogenesis and decreasing apoptosis in association with the attenuation of endoplasmic reticulum stress in islets of diabetic rats.
Kwon DY; Kim YS; Ahn IS; Kim DS; Kang S; Hong SM; Park S
J Pharmacol Sci; 2009 Dec; 111(4):361-71. PubMed ID: 20019445
[TBL] [Abstract][Full Text] [Related]
16. Roux-en-Y gastric bypass-induced improvement of glucose tolerance and insulin resistance in type 2 diabetic rats are mediated by glucagon-like peptide-1.
Liu Y; Zhou Y; Wang Y; Geng D; Liu J
Obes Surg; 2011 Sep; 21(9):1424-31. PubMed ID: 21479766
[TBL] [Abstract][Full Text] [Related]
17. Pharmacology of exenatide (synthetic exendin-4): a potential therapeutic for improved glycemic control of type 2 diabetes.
Nielsen LL; Young AA; Parkes DG
Regul Pept; 2004 Feb; 117(2):77-88. PubMed ID: 14700743
[TBL] [Abstract][Full Text] [Related]
18. Mechanisms of action of glucagon-like peptide 1 in the pancreas.
Doyle ME; Egan JM
Pharmacol Ther; 2007 Mar; 113(3):546-93. PubMed ID: 17306374
[TBL] [Abstract][Full Text] [Related]
19. A new orally available glucagon-like peptide-1 receptor agonist, biotinylated exendin-4, displays improved hypoglycemic effects in db/db mice.
Jin CH; Chae SY; Son S; Kim TH; Um KA; Youn YS; Lee S; Lee KC
J Control Release; 2009 Feb; 133(3):172-7. PubMed ID: 18977255
[TBL] [Abstract][Full Text] [Related]
20. A physiological role of glucagon-like peptide-1 receptors in the central nervous system of Suncus murinus (house musk shrew).
Chan SW; Lin G; Yew DT; Rudd JA
Eur J Pharmacol; 2011 Oct; 668(1-2):340-6. PubMed ID: 21756894
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]